Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pharos IBio Co's share price for the quarter that ended in Mar. 2024 was ₩18730. Pharos IBio Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 12.92 Mil. Therefore, Pharos IBio Co's market cap for the quarter that ended in Mar. 2024 was ₩241,972.87 Mil.
Pharos IBio Co's quarterly market cap
increased
from Sep. 2023 (₩182,157.90 Mil) to Dec. 2023 (₩191,588.77 Mil) and
increased
from Dec. 2023 (₩191,588.77 Mil) to Mar. 2024 (₩241,972.87 Mil).
Pharos IBio Co's annual market cap
stayed the same
from Dec. 2021 (₩0.00 Mil) to Dec. 2022 (₩0.00 Mil) but then
increased
from Dec. 2022 (₩0.00 Mil) to Dec. 2023 (₩191,588.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharos IBio Co's Enterprise Value for Today is ₩142,212.44 Mil.
Pharos IBio Co Market Cap Historical Data
The historical data trend for Pharos IBio Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharos IBio Co's Market Cap
For the Biotechnology subindustry, Pharos IBio Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharos IBio Co's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharos IBio Co's Market Cap falls into.
Pharos IBio Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pharos IBio Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharos IBio Co (XKRX:388870) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pharos IBio Co Market Cap Related Terms
Thank you for viewing the detailed overview of Pharos IBio Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:388870 has been successfully added to your